CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,641
- in 2 filings
Net −$701,641. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series B Preferred Stock | −2,124,143 | 0 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion | +684,167 | 684,167 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion | +1,144,973 | 1,144,973 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion | +6,895,021 | 12,205,379 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion | +6,576,400 | 11,886,758 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion | +2,124,143 | 2,124,143 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Purchase | +1,500,000 | $17.00 | $25.5M | 3,624,143 |
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series A-1 Preferred Stock | −684,167 | 0 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series A-1 Preferred Stock | −1,144,973 | 0 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series A-2 Preferred Stock | −6,895,021 | 0 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series A-2 Preferred Stock | −6,576,400 | 0 | ||
| 2023-09-19 | ARCH Venture Partners X, LLC 10% owner | Conversion · Series B Preferred Stock | −2,124,143 | 0 | ||
| 2023-09-19 | Gosebruch Henry O President & CEO | Purchase | +15,000 | $12.62 | $189K | 15,000 |
| 2023-09-19 | AMGEN INC 10% owner | Conversion | +33,603,948 | 33,603,948 | ||
| 2023-09-19 | AMGEN INC 10% owner | Purchase | +1,764,705 | $17.00 | $30.0M | 35,368,653 |
| 2023-09-19 | AMGEN INC 10% owner | Conversion · Series A-2 Preferred Stock | −32,754,291 | 0 | ||
| 2023-09-19 | AMGEN INC 10% owner | Conversion · Series B Preferred Stock | −849,657 | 0 | ||
| 2023-09-14 | Lenz Robert A. Head of R&D | Grant or award | +352,941 | 352,941 | ||
| 2023-09-14 | Lenz Robert A. Head of R&D | Grant or award · Stock Option (Right to Buy) | +502,934 | 502,934 | ||
| 2023-09-14 | Piacquad David Director | Grant or award · Stock Option (Right to Buy) | +46,455 | 46,455 |
Page 19 of 20 · 384 trades